Interactive software automates personalized radiation safety plans for Na131I therapy

Health Physics

Volumn 83, Issue 5 SUPPL., 2002, Pages

  Friedman, Marvin I ^a   Ghesani, Munir ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Operational topic; Radiation, medical; Radiopharmaceuticals; Safety standards

Indexed keywords

RADIOACTIVE MATERIAL; RADIOPHARMACEUTICAL AGENT; SODIUM IODIDE I 131;

ARTICLE; COMPUTER PROGRAM; DOSIMETRY; MAXIMUM PERMISSIBLE DOSE; NUCLEAR SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; RADIATION RESPONSE; REGULATORY MECHANISM;

EID: 0036860166     PISSN: 00179078     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004032-200211005-00008     Document Type: Article

References (37)

1. Barrington SF, Kettle AG, O'Doherty MJ, Wells CP, Somer EJR, Coakley AJ. Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid. Eur J Nucl Med 23:123-130; 1996.
2. Bajen MT, Mane S, Munoz A, Garcia JR. Effect of a diagnostic dose of 185 MBq 131I on postsurgical thyroid remnants. J Nucl Med 41:2038-2042; 2000.
3. Becker DV, Siegel BA. Guidelines for Patients Receiving Radioiodine Treatment. New York: Society of Nuclear Medicine; 1987.
4. Berman M, Hoff E, Barandes M, Becker DV, Sonenberg M, Benua R, Koutras DA. Iodine kinetics in man - A model. J Clin Endocr Metab 28:1-14; 1968.
5. Berman M, Braverman LE, Burke J, De Groot L, McCormack KR, Oddie TH, Rohrer RH, Wellman HN, Smith EM. MIRD dose estimate Report No. 5. J Nucl Med 16:857-860; 1975.
6. Cholewinski SP, Yoo KS, Klieger PS, O'Mara RE. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. J Nucl Med 41:1198-1202; 2000.
7. Clairand I, Ricard M, Gouriou J, Di Paola M, Aubert B. DOSE3D: EGS4 Monte Carlo code-based software for internal radionuclide dosimetry. J Nucl Med 40:1517-1523; 1999.
8. Clairand I, Bouchet LG, Ricard M, Durigon M, Di Paola M, Aubert B. Improvement of internal dose calculations using mathematical models of different adult heights. Phys Med Biol 45:2771-2785; 2000.
9. Cormack J, Shearer J. Calculation of radiation exposures from patients to whom radioactive materials have been administered. Phys Med Biol 43:501-516; 1998.
10. Coover LR, Silberstein EB, Kuhn PJ, Graves MW. Therapeutic 131I in outpatients: A simplified method conforming to the Code of Federal Regulations, Title 10, Part 35.75. J Nucl Med 41:1868-1875; 2000.
11. Cristy M, Eckerman KF. Specific Absorbed Fractions of Energy at Various Ages from Internal Photon Sources. Oak Ridge, TN: ORNL; Report ORNL/TM-8381/V1-V7; 1987.
12. Culver CM, Dworkin HJ. Radiation safety considerations for post-iodine-131 hyperthyroid therapy. J Nucl Med 32:169-173; 1991.
13. Culver CM, Dworkin HJ. Radiation safety considerations for post-iodine-131 thyroid cancer therapy. J Nucl Med 33:1402-1405; 1992.
14. de Klerk JMH. 131I therapy: Inpatient or outpatient?. J Nucl Med 41:1876-1878; 2000.
15. Eckerman KF, Wolbarst AB, Richardson ACB. Limiting Values of Radionuclide Intake and Air Concentration and Dose Conversion Factors for Inhalation, Submersion, and Ingestion. Washington, DC: U.S. Environmental Protection Agency; Federal Guidance Report No. 11; 1988.
16. 131I-therapy. J Nucl Med 39:189P; 1998.
17. 131I radionuclide therapy and radioimmunotherapy. J Nucl Med 41:237P; 2000.
18. Howell RW, Wessels BW, Loevinger R. The MIRD perspective 1999. J Nucl Med 40:3S-10S; 1999.
19. International Commission on Radiological Protection. Recommendations of the International Commission on Radiological Protection. Oxford: Pergamon Press; ICRP Publication 26; 1977.
20. International Commission on Radiological Protection. 1990 Recommendations of the International Commission on Radiological Protection. Oxford: Pergamon Press; ICRP Publication 60, Ann ICRP; 1991.
21. Jeevanram RK, Shah DH, Sharma SM, Ganatra RD. Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients. Nucl Med Biol 13(3):277-279; 1986.
22. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, Crawford SM, Burgess JM, Petry NA, Butchko GM, Glenn SD, Wahl RL. Radioimmunotherapy of B-cell lymphoma with [13II]anti-B1 (anti-CD20) antibody. N Engl J Med 329:459-465; 1993.
23. Mountford PJ. Estimation of close contact doses to young infants from surface dose rates on radioactive adults. Nucl Med Commun 8:857-863; 1987.
24. National Council on Radiation Protection and Measurements. Precautions in the Management of Patients Who have Received Therapeutic Amounts of Radionuclides. Washington, DC: NCRP; Report No. 37; 1970.
25. National Council on Radiation Protection and Measurements. Limitation of Exposure to Ionizing Radiation. Bethesda, MD: NCRP; Report No. 116; 1993.
26. National Council on Radiation Protection and Measurements. Dose Limits for Individuals Who Receive Exposure from Radionuclide Therapy Patients. Bethesda, MD: NCRP; Commentary No. 11; 1995.
27. O'Doherty MJ, Kettle AG, Eustance CNP, Mountford PJ, Coakley AJ. Radiation dose rates from adult patients receiving 131I therapy for thyrotoxicosis. Nucl Med Commun 14:160-168; 1993.
28. Robinson PS, Barker P, Campbell A, Henson P, Surveyor I, Young PR. Iodine-131 in breast milk following therapy for thyroid carcinoma. J Nucl Med 35:1797-1801; 1994.
29. Schneider S, McGuire SA. Regulatory Analysis on Criteria for the Release of Patients Administered Radioactive Material. Washington, DC: US Nuclear Regulatory Commission; NUREG-1492; 1997.
30. Siegel JA. Revised Nuclear Regulatory Commission regulations for release of patients administered radioactive materials: Outpatient iodine-131 anti-B1 therapy. J Nucl Med 39(Suppl):28S-33S; 1998.
31. Sorensen JA, Phelps ME. Physics in Nuclear Medicine. Olrando, FL: Grune & Stratton/Harcourt Brace Jovanovich; 1987.
32. Sparks RB, Siegel JA, Wahl RL. The need for better methods to determine release criteria for patients administered radioactive material. Health Phys 75:385-388; 1998.
33. Stabin MG, Breitz HB. Breast milk excretion of radiopharmaceuticals: Mechanisms, findings, and radiation dosimetry. J Nucl Med 41:863-873; 2000.
34. US Nuclear Regulatory Commission. Criteria for the Release of Individuals Administered Radioactive Material. Washington, DC: US NRC; Vol. 62 FR 4133, 10 CFR Part 35.75; 1997a.
35. US Nuclear Regulatory Commission. Release of Patients Administered Radioactive Materials. Washington, DC: U.S. NRC; Regulatory Guide 8.39; 1997b.
36. Yeung HWD, Humm JL, Larson SM. Radioiodine uptake in thyroid remnants during therapy after tracer dosimetry. J Nucl Med 41:1082-1085; 2000.
37. Zanzonico PB, Siegel JA, St. Germain J. A generalized algorithm for determining the time of release and the duration of post-release radiation precautions following radionuclide therapy. Health Phys 78:648-659; 2000.